Alan Henry Raffensperger

Directeur/Membre du Conseil chez SPAGO NANOMEDICAL AB

Profil

Alan Henry Raffensperger is currently the Chief Executive Officer at Swedemed Ab and the Director at Masimo Sweden AB.
He is also a Director at Spago Nanomedical AB, Rolf Lufts Stiftelse Foer Diabetesforskning, and Inceptua Ltd.
Dr. Raffensperger previously served as the Chief Executive Officer at BeneChill, Inc. from 2010 to 2012.
He was also the Chief Executive Officer at Inceptua SA and the Chairman at Palette Life Sciences AB.
Additionally, Dr. Raffensperger worked as the Director-Sales & Marketing at Roche Pharmaceuticals, Inc. from 1996 to 2004 and as the Business Director at Roche Diagnostics GmbH from 1994 to 1996.
He has also held positions as a Director at Metracor Technologies, Inc., Xvivo Perfusion AB, and Amgen International AG.
From 2012 to 2017, Dr. Raffensperger served as the Chief Operating Officer & Senior Vice President at Swedish Orphan Biovitrum AB.
He holds an MBA from George Washington University, an undergraduate degree from the University of Maryland, and a doctorate from the University of Minnesota.

Postes actifs de Alan Henry Raffensperger

Sociétés	Poste	Début
SPAGO NANOMEDICAL AB	Directeur/Membre du Conseil	10/05/2023
Inceptua Ltd.	Directeur/Membre du Conseil	17/10/2018
Masimo Sweden AB	Directeur/Membre du Conseil	-
Swedemed Ab	Directeur Général	12/08/2011
Rolf Lufts Stiftelse Foer Diabetesforskning	Directeur/Membre du Conseil	-

Anciens postes connus de Alan Henry Raffensperger

Sociétés	Poste	Fin
XVIVO PERFUSION AB	Directeur/Membre du Conseil	01/04/2020
SWEDISH ORPHAN BIOVITRUM AB	Directeur des opérations	07/06/2017
BeneChill, Inc.	Directeur Général	01/01/2012
Amgen International AG	Directeur/Membre du Conseil	01/01/2010
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░ ░ ░░░░░░░░░	░░░░░░░░░░

Formation de Alan Henry Raffensperger

George Washington University	Masters Business Admin
University of Maryland	Undergraduate Degree
University of Minnesota	Doctorate Degree